Phase I/II clinical trials are currently in progress in order to investigate CAR-T cells targeting MUC16 (NCT02498912), mesothelin (NCT01583686), and NY-ESO-1 (NCT01567891 and NCT02457650) for ovarian cancer. This evidence concerns the gene MSLN and ovarian carcinoma.